Autem Therapeutics

Autem Therapeutics is a biotechnology startup based in Hanover NH, USA, established in 2019. The company is focused on developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers. Their proprietary AutEMsys™ therapy, which delivers personalized, amplitude-modulated electromagnetic (EM) frequencies, has received FDA breakthrough designation for the treatment of advanced HCC patients. Initial clinical feasibility studies have shown promising results in shrinking cancerous tumors, enhancing quality of life, and extending survival in early and advanced stage cancer patient populations. In June 2022, Autem Therapeutics secured a $10.00M Series A investment from Zentynel Frontier Investments. The investment signifies a strong vote of confidence in the potential of Autem's innovative therapy. The company is gearing up to submit an FDA Investigational Device Exemption (IDE) to initiate pivotal clinical trials in late 2022 or early 2023, marking a significant milestone in the advancement of their groundbreaking treatment approach.